SEOM clinical guideline for secondary prevention (2019)
-
A. Santaballa [7] ; Á. Pinto [1] ; R. P. Balanyà [8] ; N. Ramírez Merino [9] ; I. R. Martín [2] ; S. S. Grau [10] ; J. P. B. Fombella [3] ; J. M. Cano [4] ; C. H. González [5] ; J. Bayo [6]
-
[1] Hospital Universitario La Paz
Hospital Universitario La Paz
Madrid, España
-
[2] Complejo Asistencial Universitario de Palencia
Complejo Asistencial Universitario de Palencia
Palencia, España
-
[3] Hospital Universitario Central de Asturias
Hospital Universitario Central de Asturias
Oviedo, España
-
[4] Hospital General de Ciudad Real
Hospital General de Ciudad Real
Ciudad Real, España
-
[5] Hospital Universitario Marqués de Valdecilla
Hospital Universitario Marqués de Valdecilla
Santander, España
-
[6] Hospital Juan Ramón Jiménez
Hospital Juan Ramón Jiménez
Huelva, España
-
[7] Hospital Universitari i Politècnic la Fe
-
[8] Hospital Universitari Doctor Josep Trueta
-
[9] Centro Integral Oncológico Clara Campal
-
[10] Hospital Universitario de Gran Canaria Dr. Negrín
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 2 (February), 2020 (Ejemplar dedicado a: Clinical Guides in Oncology), págs. 187-192
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Cancer is one of the major public health problems in our society. It is estimated that more than 18 million new cases are diagnosed worldwide every year; 280,000 in Spain. Incidence in following a growing trend. This epidemic could be controlled with research into new treatments and, above all, with adequate prevention. Primary prevention could prevent avoid up to half of all cases. For many others, secondary prevention is essential, as it make diagnosis possible in the stages of the disease when it is easily curable. These guidelines present the scientific evidence regarding secondary prevention in tumors in which its use is well-accepted: breast, cervical, colorectal, prostate, lung, ovarian, melanoma, and gastric cancer.
